Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

ADAM23 Negatively Modulates alpha(v)beta(3) Integrin Activation during Metastasis

Full text
Author(s):
Show less -
Verbisck, Newton V. ; Costa, Erico T. ; Costa, Fabricio F. ; Cavalher, Felicia P. ; Costa, Michele D. M. [1] ; Muras, Angelita [2] ; Paixao, Valeria A. ; Moura, Ricardo ; Granato, Mariana F. ; Ierardi, Daniela F. ; Machado, Tamara ; Melo, Fabiana [3] ; Ribeiro, Karina B. [4] ; Cunha, Isabela W. [4] ; Lima, Vladmir C. C. [4] ; Maciel, Maria do Socorro [4] ; Carvalho, Andre L. [4] ; Soares, Fernando F. [4] ; Zanata, Silvio [1] ; Sogayar, Mari C. [2] ; Chammas, Roger [3] ; Camargo, Anamaria A. [5]
Total Authors: 22
Affiliation:
[1] Univ Fed Parana, Dept Pathol, BR-80060000 Curitiba, Parana - Brazil
[2] Univ Sao Paulo, Dept Biochem, Inst Chem, Fac Med, BR-05508 Sao Paulo - Brazil
[3] Univ Sao Paulo, Dept Radiol, Fac Med, BR-05508 Sao Paulo - Brazil
[4] AC Camargo Hosp, Sao Paulo - Brazil
[5] Hosp Alemao Oswaldo Cruz, Ludwig Inst Canc Res, Lab Mol Biol & Genom, BR-01323903 Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: Cancer Research; v. 69, n. 13, p. 5546-5552, JUL 1 2009.
Web of Science Citations: 38
Abstract

The ADAM23 gene is frequently silenced in different types of tumors, and, in breast tumors, silencing is correlated with tumor progression, suggesting that it might be associated with the acquisition of a metastatic phenotype. ADAM23 exerts its function mainly through the disintegrin domain, because its metalloprotease domain is inactive. Analysis of ADAM23 binding to integrins has revealed a specific interaction with alpha(v)beta(3) integrin mediated by the disintegrin domain. Altered expression of alpha(v)beta(3) integrin has been observed in different types of tumors, and expression of this integrin in the activated form has been shown to promote metastasis formation. Here, we investigated the possibility that interaction between ADAM23 and alpha(v)beta(3) integrin might negatively modulate alpha(v)beta(3) activation during metastatic progression. ADAM23 expression was knocked down using short hairpin RNA in the MDA-MB-435 cell line, which has been extensively used as a model for alpha(v)beta(3) integrin activation. Ablation of ADAM23 enhanced alpha(v)beta(3) integrin activation by at least 2- to 4-fold and ADAM23 knockdown cells showed enhanced migration and adhesion to classic alpha(v)beta(3) integrin ligands. Ablation of ADAM23 expression also enhanced pulmonary tumor cell arrest in immunodeficient mice. To complement our findings with clinical evidence, we showed that silencing of ADAM23 gene by DNA promoter hypermethylation in a collection of 94 primary breast tumors was significantly associated with lower distant metastases-free and disease-specific survivals and was an independent prognostic factor for poor disease outcome. Our results strongly support a functional role of ADAM23 during metastatic progression by negatively modulating alpha(v)beta(3) integrin activation. {[}Cancer Res 2009;69(13):5546-52] (AU)